Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$30.83 USD

30.83
634,920

-0.20 (-0.64%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $30.83 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 244)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Omnicell (OMCL) Down 7.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking

by Zacks Equity Research

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Zacks Equity Research

Omnicell, Pharmaceutical Strategies Enter Acquisition Deal

by Zacks Equity Research

Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.

Zacks Equity Research

Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.

Zacks Equity Research

Omnicell (OMCL) Q2 Earnings Lag Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of -13.95% and 0.50%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

New Strong Sell Stocks for June 25th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

HMSY or OMCL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HMSY vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Omnicell (OMCL) Q1 Earnings Top, Operating Margin Rises

by Zacks Equity Research

Omnicell's (OMCL) Q1 revenues suffer due to slowdown in hospital purchasing decisions and product bookings.

Zacks Equity Research

Earnings Preview: Omnicell (OMCL) Q1 Earnings Expected to Decline

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Omnicell (OMCL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CPSI or OMCL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

CPSI or OMCL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

CPSI vs. OMCL: Which Stock Is the Better Value Option?

Zacks Equity Research

Why You Shouldn't Bet Against Omnicell (OMCL) Stock

by Zacks Equity Research

Omnicell (OMCL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Why Is Omnicell (OMCL) Down 5% Since Last Earnings Report?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold on to Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Omnicell (OMCL) on its strong segmental performance in Q4.

Zacks Equity Research

Omnicell-Geisinger Deal Improves Patient Care via Automation

by Zacks Equity Research

Omnicell's (OMCL) XT series Automated Dispensing Systems partners with Geisinger to streamline nursing workflow and improve patient care.

Zacks Equity Research

Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues

by Zacks Equity Research

Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.

Zacks Equity Research

Omnicell (OMCL) Misses Q4 Earnings Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of -1.28% and 2.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Omnicell (OMCL) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Hill-Rom (HRC) Gains Ground on Global Expansion, New Menu

by Zacks Equity Research

Hill-Rom (HRC) is optimistic about its latest buyouts of Breathe Technologies and Voalte, mirroring its outstanding capital management strategy in turn.

Zacks Equity Research

Here's Why You Should Retain Edwards Lifesciences Stock Now

by Zacks Equity Research

Investors can hold on to Edwards Lifesciences (EW) in their portfolio for now, thanks to solid prospects.

Zacks Equity Research

Hologic (HOLX) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Hologic (HOLX) gains from several positive developments.

Zacks Equity Research

Integra Announces Preliminary Q4 Results, Share Buyback Plan

by Zacks Equity Research

Integra (IART) projects fourth-quarter 2019 revenues at or near the low end of its previously-announced guidance.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now

by Zacks Equity Research

Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.